WVE

Wave Life Sciences Ltd

WVE, USA

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

https://wavelifesciences.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
WVE
stock
WVE

Why Wave Life Sciences Shares Are on the Move TipRanks

Read more →
WVE
stock
WVE

Wave Life Sciences Announces Public Offering for $402.5 Million TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$19.8

Analyst Picks

Strong Buy

9

Buy

3

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

22.30

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-43.24 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-22.31 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-590.35 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

0.94

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 86.98% of the total shares of Wave Life Sciences Ltd

1.

RA Capital Management, LLC

(11.4315%)

since

2025/06/30

2.

Adage Capital Partners Gp LLC

(9.4309%)

since

2025/06/30

3.

BlackRock Inc

(6.5213%)

since

2025/06/30

4.

Maverick Capital Ltd

(5.1886%)

since

2025/06/30

5.

Driehaus Capital Management LLC

(4.102%)

since

2025/06/30

6.

M28 Capital Management LP

(3.5575%)

since

2025/06/30

7.

T. Rowe Price Associates, Inc.

(3.2597%)

since

2025/06/30

8.

Kynam Capital Management, LP

(2.8639%)

since

2025/06/30

9.

683 Capital Management LLC

(2.5749%)

since

2025/06/30

10.

Bellevue Group AG

(2.5715%)

since

2025/06/30

11.

BB Biotech AG Ord

(2.5715%)

since

2024/12/31

12.

Siren, L.L.C.

(2.3214%)

since

2025/06/30

13.

Vanguard Group Inc

(2.1837%)

since

2025/06/30

14.

Loomis, Sayles & Company LP

(2.0698%)

since

2025/06/30

15.

Emerald Advisers, LLC

(2.0456%)

since

2025/06/30

16.

Geode Capital Management, LLC

(1.733%)

since

2025/06/30

17.

State Street Corp

(1.7313%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(1.6963%)

since

2025/08/31

19.

PRIMECAP Management Company

(1.5486%)

since

2025/06/30

20.

PRIMECAP Odyssey Aggressive Growth

(1.5031%)

since

2025/06/30

21.

Artisan Partners Limited Partnership

(1.4224%)

since

2025/06/30

22.

US Small-Cap Growth II Equity Comp

(1.3362%)

since

2025/06/30

23.

T. Rowe Price New Horizons

(1.3339%)

since

2025/07/31

24.

Affinity Asset Advisors, LLC

(1.2563%)

since

2025/06/30

25.

Emerald Mutual Fund Advisers Trust

(1.2168%)

since

2025/06/30

26.

Loomis Sayles Small Cap Growth Instl

(1.138%)

since

2025/07/31

27.

Artisan Non-U.S. Small-Mid Growth Comp

(0.9511%)

since

2025/06/30

28.

Artisan International Small-Mid Investor

(0.9511%)

since

2025/06/30

29.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8062%)

since

2025/07/31

30.

Fidelity Small Cap Index

(0.7065%)

since

2025/06/30

31.

T. Rowe Price Health Sciences

(0.669%)

since

2025/07/31

32.

Polar Capital Biotech S Inc

(0.628%)

since

2025/07/31

33.

Emerald Growth A

(0.6047%)

since

2025/07/31

34.

iShares Russell 2000 Growth ETF

(0.5521%)

since

2025/08/31

35.

iShares Biotechnology ETF

(0.4627%)

since

2025/08/31

36.

Principal SmallCap Growth I Instl

(0.4408%)

since

2025/07/31

37.

Heptagon Driehaus US Micro Cap Eq C$ Acc

(0.4096%)

since

2025/07/31

38.

Fidelity Extended Market Index

(0.4044%)

since

2025/07/31

39.

T. Rowe Price New Horizons Tr-A

(0.3915%)

since

2025/06/30

40.

Driehaus Small Cap Growth Institutional

(0.3908%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.32

EPS Estimate

-0.2547

EPS Difference

-0.0653

Surprise Percent

-25.638%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Strong Momentum(7)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.